Aluminium and Aluminium Alloy Products
Aluminium and Aluminium Alloy Foil for Pharmaceutical Packaging
Strategic Recommendations for Aluminium and Aluminium Alloy Foil for Pharmaceutical Packaging — IS 16011 : 2012
- Start BIS Certification Immediately
Manufacturers and importers should initiate BIS certification under Scheme-I on priority, as compliance is effective immediately under S.O. 1319(E) dated 11 March 2026, leaving no transition window. - Engage ERA Compliance Experts
ERA provides end-to-end support including BIS application filing, coordination with BIS-recognised laboratories, factory audit preparation, validation of pharmaceutical-grade manufacturing processes, and ISI marking approval to ensure timely and compliant market entry. - Reach Out for Support
For product scope validation, documentation assistance, and accelerated certification timelines, stakeholders may connect with ERA’s compliance team.
📧 cs@eraglobal.co.in | 📞 +91 9599296331 | 💬 WhatsApp Support Available - Track Gazette Notifications and Amendments
Stay updated with future regulatory changes, BIS amendments, and packaging-related compliance updates by tracking Gazette notifications and subscribing to the ERA Newsletter for timely alerts. - Ensure ISI Marking and Pharma-grade Compliance Control
Only BIS-certified aluminium foil conforming to IS 16011:2012 and bearing the ISI Mark should be manufactured or supplied. Strict control over hygiene, barrier properties, and contamination prevention must be maintained, and non-certified stock must not enter the pharmaceutical supply chain.
| Section | Details |
|---|---|
| Product Name | Aluminium and Aluminium Alloy Foil for Pharmaceutical Packaging. |
| Applicable Indian Standard (IS) No. | IS 16011:2012. |
| Title of Indian Standard | Aluminium and aluminium alloy foil for pharmaceutical packaging. |
| QCO Coverage | Covered under Aluminium and Aluminium Alloy Products (Quality Control) regulatory framework. |
| Latest Governing Notification | Aluminium and Aluminium Alloy Products (Quality Control) Order, 2026 – S.O. 1319(E), dated 11 March 2026, issued by the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry. |
| Supersession History | Supersedes the Aluminium and Aluminium Alloy Products (Quality Control) Order, 2025, except for actions taken prior to such supersession. |
| Enforcement Date (Category-wise) |
General Enterprises: With immediate effect, Small Enterprises: With immediate effect, Micro Enterprises: With immediate effect. |
| Objective & Scope | To ensure that aluminium foil used in pharmaceutical packaging meets stringent requirements for purity, barrier properties, mechanical strength, and hygiene, ensuring safety and integrity of medicinal products. |
| Products Covered | Aluminium and aluminium alloy foils used for pharmaceutical packaging applications such as blister packs, strip packs, and other protective medicinal packaging, conforming to IS 16011:2012. |
| Exemptions | Goods manufactured exclusively for export; limited exemption for R&D imports up to 200 kg per year; other exemptions subject to conditions specified in the Order. |
| Industries Impacted | Aluminium foil manufacturers, pharmaceutical packaging manufacturers, pharma companies, contract packaging firms, importers, distributors, and healthcare supply chain stakeholders. |
| Mandatory Compliance | Products must conform to IS 16011:2012 and bear the ISI Mark under a valid BIS licence (Scheme-I) prior to manufacture, import, sale, or distribution in India. |
| Certification, Enforcement & Legal Framework | Certification and enforcement are carried out by the Bureau of Indian Standards (BIS) under the BIS Act, 2016 and Scheme-I of Schedule-II of BIS (Conformity Assessment) Regulations, 2018. |
| Penalties for Non-Compliance | Punishable under the BIS Act, 2016, including imprisonment, monetary fines, or both, along with additional penalties for continued violations. |
| Supersession & Amendment Clause | The latest version of IS 16011, including amendments notified by BIS from time to time, applies automatically from the date of such notification as specified in the Order. |
| Next Steps for Stakeholders | Identify applicable foil specifications , initiate BIS certification, conduct testing in BIS-recognised laboratories, ensure compliance with pharmaceutical-grade requirements, obtain BIS licence, affix ISI Mark, ensure only certified products are supplied in the market. |
| Conclusion | BIS certification for aluminium foil used in pharmaceutical packaging as per IS 16011:2012 is mandatory with immediate effect. Timely compliance is essential to ensure uninterrupted supply and regulatory adherence. |
Ready to start your certification journey?
Let us help you navigate regulatory challenges and achieve certification with ease. Leave us your details, and we’ll get back to you—or request a free consultation today.
Get in touch with us today
Notification
Aluminium and Aluminium Alloy Foil for Pharmaceutical Packaging has been brought under mandatory quality control through the Aluminium and Aluminium Alloy Products (Quality Control) Order, 2026, notified vide S.O. 1319(E) dated 11 March 2026 by the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry. This Order supersedes the Aluminium and Aluminium Alloy Products (Quality Control) Order, 2025, except in respect of actions taken or omitted before such supersession. The Order mandates conformity to IS 16011:2012 – Aluminium and aluminium alloy foil for pharmaceutical packaging.
Enforcement Timeline
As per the implementation schedule specified in S.O. 1319(E) dated 11 March 2026, mandatory compliance applies with immediate effect for general enterprises, small enterprises, and micro enterprises.
Overview
The regulatory framework mandates that aluminium foil used in pharmaceutical packaging must comply with strict quality and safety parameters. IS 16011:2012 defines requirements related to material purity, barrier properties, thickness uniformity, mechanical strength, and hygiene standards essential for protecting medicines from moisture, light, and contamination. The regulation ensures integrity and safety of pharmaceutical products across the supply chain.
Objective & Scope
The primary objective is to safeguard public health by ensuring that pharmaceutical packaging materials do not compromise the quality or efficacy of medicinal products. The scope covers manufacture, import, sale, and distribution of aluminium foil used in pharmaceutical packaging within India. Products manufactured exclusively for export are exempt, subject to specified conditions.
Products Covered
The Order covers aluminium and aluminium alloy foils used in pharmaceutical packaging applications such as blister packs, strip packs, and other medicinal packaging formats, conforming to IS 16011:2012.
Exemptions Provided
Limited exemptions are provided for goods manufactured exclusively for export and for research and development imports up to 200 kg per year, subject to non-commercial use and record-keeping requirements.
Industries Impacted
The regulation impacts aluminium foil manufacturers, pharmaceutical packaging companies, drug manufacturers, contract packaging firms, importers, distributors, and stakeholders across the healthcare and packaging ecosystem.
Mandatory Compliance Requirements
Manufacturers and importers must obtain BIS certification under Scheme-I, ensure testing in BIS-recognised laboratories, comply with factory inspection and quality assurance requirements, and affix the ISI Mark on compliant products before they are introduced into the Indian market.
Next Steps for Stakeholders
Stakeholders should immediately identify applicable product categories, initiate BIS certification, align manufacturing and quality systems with IS 16011:2012 requirements, conduct required testing, and ensure readiness due to immediate enforcement.
Legal Provisions & Penalties
Certification and enforcement are administered by the Bureau of Indian Standards (BIS) under the BIS Act, 2016. Non-compliance may result in penalties including imprisonment, fines, or both, along with additional penalties for continued violations.
Conclusion
Compliance with IS 16011:2012 and BIS certification is mandatory with immediate effect. Timely adherence is critical to ensure uninterrupted market access, product safety, and regulatory compliance in the pharmaceutical sector.
Ready to start your certification journey?
Let us help you navigate regulatory challenges and achieve certification with ease. Leave us your details, and we’ll get back to you—or request a free consultation today.